Literature DB >> 9608402

Magnetic resonance spectroscopy in affective disorders.

T Kato1, T Inubushi, N Kato.   

Abstract

Magnetic resonance spectroscopy (MRS) is a non-invasive tool for in vivo chemical analysis that has been applied to neurobiological or psychopharmacological studies of affective disorders. Studies employing 31P-MRS and 1H-MRS have indicated possible abnormalities in membrane phospholipid metabolism, high-energy phosphate metabolism, and intracellular pH in affective disorders. They have also suggested that lithium increases the phosphomonoester (possibly inositol-1-phosphate) peak in the brain but does not increase that of choline-containing compounds in the brain. Studies employing 7Li-MRS and 19F-MRS have elucidated the pharmacokinetic properties of lithium, fluoxetine, and fluvoxamine in the brain in patients treated with these drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9608402     DOI: 10.1176/jnp.10.2.133

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  22 in total

Review 1.  The contribution of neuroimaging to the study of language and aphasia.

Authors:  Andrew Lee; Vijay Kannan; Argye E Hillis
Journal:  Neuropsychol Rev       Date:  2006-12       Impact factor: 7.444

2.  Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder.

Authors:  Xiujun Sun; Jun-Feng Wang; Michael Tseng; L Trevor Young
Journal:  J Psychiatry Neurosci       Date:  2006-05       Impact factor: 6.186

3.  Modulatory effects of neuropsychopharmaca on intracellular pH of hippocampal neurones in vitro.

Authors:  Udo Bonnet; Dieter Bingmann; Jens Wiltfang; Norbert Scherbaum; Martin Wiemann
Journal:  Br J Pharmacol       Date:  2009-12-10       Impact factor: 8.739

Review 4.  Mitochondrial dysfunction as the molecular basis of bipolar disorder: therapeutic implications.

Authors:  Tadafumi Kato
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

5.  Effects of Mood Stabilizers on Brain Energy Metabolism in Mice Submitted to an Animal Model of Mania Induced by Paradoxical Sleep Deprivation.

Authors:  Emilio L Streck; Giselli Scaini; Gabriela C Jeremias; Gislaine T Rezin; Cinara L Gonçalves; Gabriela K Ferreira; Gislaine Z Réus; Wilson R Resende; Samira S Valvassori; Flávio Kapczinski; Mônica L Andersen; João Quevedo
Journal:  Neurochem Res       Date:  2015-04-17       Impact factor: 3.996

6.  The relevance between symptoms and magnetic resonance imaging analysis of the hippocampus of depressed patients given electro-acupuncture combined with Fluoxetine intervention - A randomized, controlled trial.

Authors:  Dong-Mei Duan; Ya Tu; Shuang Jiao; Wen Qin
Journal:  Chin J Integr Med       Date:  2011-02-27       Impact factor: 1.978

7.  Decrease in creatine kinase messenger RNA expression in the hippocampus and dorsolateral prefrontal cortex in bipolar disorder.

Authors:  Matthew L MacDonald; Alipi Naydenov; Melissa Chu; David Matzilevich; Christine Konradi
Journal:  Bipolar Disord       Date:  2006-06       Impact factor: 6.744

Review 8.  The Utility of Magnetic Resonance Spectroscopy for Understanding Substance Use Disorders: A Systematic Review of the Literature.

Authors:  Tracy Hellem; Xianfeng Shi; Gwen Latendresse; Perry F Renshaw
Journal:  J Am Psychiatr Nurses Assoc       Date:  2015 Jul-Aug       Impact factor: 2.385

Review 9.  Mitochondrial dysfunction and psychiatric disorders.

Authors:  Gislaine T Rezin; Graziela Amboni; Alexandra I Zugno; João Quevedo; Emilio L Streck
Journal:  Neurochem Res       Date:  2008-11-01       Impact factor: 3.996

10.  Evaluation of brain creatine kinase activity in an animal model of mania induced by ouabain.

Authors:  Tiago P Freitas; Giselli Scaini; Cristiane Corrêa; Patricia M Santos; Gabriela K Ferreira; Gislaine T Rezin; Morgana Moretti; Samira S Valvassori; João Quevedo; Emilio L Streck
Journal:  J Neural Transm (Vienna)       Date:  2010-02       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.